-+ 0.00%
-+ 0.00%
-+ 0.00%

3 Asian Stocks Estimated To Be Trading At Up To 47.2% Below Intrinsic Value

Simply Wall St·08/03/2026 04:07:50
Listen to the news

As the Asian markets navigate a landscape marked by fluctuating global sentiment and economic adjustments, investors are increasingly on the lookout for opportunities in undervalued stocks. In this environment, identifying stocks trading below their intrinsic value can offer potential advantages, especially when these companies demonstrate strong fundamentals and resilience amidst broader market uncertainties.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Name Current Price Fair Value (Est) Discount (Est)
Zijin Gold International (SEHK:2259) HK$118.20 HK$231.87 49%
Visional (TSE:4194) ¥8713.00 ¥17403.67 49.9%
Pan-United (SGX:P52) SGD1.61 SGD3.16 49.1%
Nippon Thompson (TSE:6480) ¥1782.00 ¥3500.64 49.1%
Lotes (TWSE:3533) NT$1855.00 NT$3663.21 49.4%
Livero (TSE:9245) ¥2100.00 ¥4133.74 49.2%
Jiangsu Azure (SZSE:002245) CN¥15.88 CN¥31.24 49.2%
EZconn (TWSE:6442) NT$1155.00 NT$2269.15 49.1%
CanSino Biologics (SEHK:6185) HK$23.28 HK$45.77 49.1%
Baycurrent (TSE:6532) ¥7139.00 ¥14082.15 49.3%

Click here to see the full list of 218 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Shanghai MicroPort MedBot (Group) (SEHK:2252)

Overview: Shanghai MicroPort MedBot (Group) Co., Ltd. operates in the medical technology sector, focusing on the development and manufacturing of surgical robots, with a market cap of HK$21.47 billion.

Operations: The company's revenue is derived from the sale of medical devices, totaling CN¥551.07 million.

Estimated Discount To Fair Value: 47.2%

Shanghai MicroPort MedBot (Group) is trading at HK$20.82, significantly below its estimated future cash flow value of HK$39.44, suggesting it may be undervalued. The company recently announced a turnaround to profitability with an expected net profit of RMB 28 million to RMB 40 million for H1 2026, driven by substantial revenue growth and improved gross margins. Forecasts indicate annual revenue growth of 30.3%, outpacing the Hong Kong market's average, enhancing its investment appeal based on cash flows.

SEHK:2252 Discounted Cash Flow as at Aug 2026
SEHK:2252 Discounted Cash Flow as at Aug 2026

Softcare (SEHK:2698)

Overview: Softcare Limited is a hygiene product corporation focused on developing, manufacturing, and selling baby and feminine hygiene products in Africa, Latin America, and Central Asia with a market cap of HK$21.09 billion.

Operations: The company generates revenue of $567.39 million from its personal products segment, which includes baby and feminine hygiene items across Africa, Latin America, and Central Asia.

Estimated Discount To Fair Value: 35.8%

Softcare is trading at HK$34.04, undervalued relative to its future cash flow estimate of HK$53.02. The company's revenue and earnings are forecast to grow faster than the Hong Kong market, with recent guidance indicating a 28% revenue increase and a 40% profit rise for H1 2026 compared to H1 2025. Factors such as increased sales volume, higher selling prices, and improved income from bank deposits contribute to its financial strength despite non-cash earnings considerations.

SEHK:2698 Discounted Cash Flow as at Aug 2026
SEHK:2698 Discounted Cash Flow as at Aug 2026

Guangdong Songfa CeramicsLtd (SHSE:603268)

Overview: Guangdong Songfa Ceramics Co., Ltd. produces and sells ceramic products both in China and internationally, with a market cap of CN¥148.14 billion.

Operations: Guangdong Songfa Ceramics Co., Ltd. generates its revenue through the production and sale of ceramic products both domestically and internationally.

Estimated Discount To Fair Value: 29.0%

Guangdong Songfa Ceramics Ltd. trades at CN¥152.6, below its estimated future cash flow value of CN¥215.06, suggesting undervaluation by more than 20%. Forecasts predict revenue growth of 23.6% annually and earnings growth of 28.7%, outpacing the Chinese market averages. Despite high non-cash earnings and debt not well covered by operating cash flow, recent private placements raised approximately CN¥6.94 billion, bolstering financial resources for potential expansion or debt management.

SHSE:603268 Discounted Cash Flow as at Aug 2026
SHSE:603268 Discounted Cash Flow as at Aug 2026

Turning Ideas Into Actions

Curious About Other Options?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.